Last reviewed · How we verify

gadoxetic acid enhanced liver MRI

Seoul National University Hospital · FDA-approved active Small molecule

gadoxetic acid enhanced liver MRI is a Gadolinium-based contrast agent Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved for Liver MRI for detection and characterization of focal hepatic lesions, Evaluation of cirrhosis and hepatocellular carcinoma. Also known as: Primovist, Eovist.

Gadoxetic acid is a gadolinium-based contrast agent that accumulates in hepatocytes to enhance MRI visualization of liver tissue and detect lesions.

Gadoxetic acid is a gadolinium-based contrast agent that accumulates in hepatocytes to enhance MRI visualization of liver tissue and detect lesions. Used for Liver MRI for detection and characterization of focal hepatic lesions, Evaluation of cirrhosis and hepatocellular carcinoma.

At a glance

Generic namegadoxetic acid enhanced liver MRI
Also known asPrimovist, Eovist
SponsorSeoul National University Hospital
Drug classGadolinium-based contrast agent
TargetOrganic anion transporter 1B1/1B3 (OATP1B1/1B3)
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhaseFDA-approved

Mechanism of action

Gadoxetic acid is a hepatobiliary contrast agent containing gadolinium that is taken up by hepatocytes via organic anion transporters and excreted into bile. This dual uptake mechanism allows for both vascular phase imaging (from the gadolinium contrast effect) and hepatobiliary phase imaging (from hepatocyte accumulation), improving detection and characterization of focal liver lesions on MRI.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about gadoxetic acid enhanced liver MRI

What is gadoxetic acid enhanced liver MRI?

gadoxetic acid enhanced liver MRI is a Gadolinium-based contrast agent drug developed by Seoul National University Hospital, indicated for Liver MRI for detection and characterization of focal hepatic lesions, Evaluation of cirrhosis and hepatocellular carcinoma.

How does gadoxetic acid enhanced liver MRI work?

Gadoxetic acid is a gadolinium-based contrast agent that accumulates in hepatocytes to enhance MRI visualization of liver tissue and detect lesions.

What is gadoxetic acid enhanced liver MRI used for?

gadoxetic acid enhanced liver MRI is indicated for Liver MRI for detection and characterization of focal hepatic lesions, Evaluation of cirrhosis and hepatocellular carcinoma.

Who makes gadoxetic acid enhanced liver MRI?

gadoxetic acid enhanced liver MRI is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

Is gadoxetic acid enhanced liver MRI also known as anything else?

gadoxetic acid enhanced liver MRI is also known as Primovist, Eovist.

What drug class is gadoxetic acid enhanced liver MRI in?

gadoxetic acid enhanced liver MRI belongs to the Gadolinium-based contrast agent class. See all Gadolinium-based contrast agent drugs at /class/gadolinium-based-contrast-agent.

What development phase is gadoxetic acid enhanced liver MRI in?

gadoxetic acid enhanced liver MRI is FDA-approved (marketed).

What are the side effects of gadoxetic acid enhanced liver MRI?

Common side effects of gadoxetic acid enhanced liver MRI include Gadolinium deposition in tissues, Nephrogenic systemic fibrosis (rare, in severe renal impairment), Injection site reactions, Headache, Nausea.

What does gadoxetic acid enhanced liver MRI target?

gadoxetic acid enhanced liver MRI targets Organic anion transporter 1B1/1B3 (OATP1B1/1B3) and is a Gadolinium-based contrast agent.

Related